Cautionary Note Regarding Forward-Looking Statements 1 Year-Two Real-World Analysis of Glucagon-Like Peptide-1 Agonist (GLP-1) Obesity Treatment Adherence and Persistency, Prime Therapeutics/Magellan RX Management, 2024 NEW YORK, July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees b ...

Core Insights - The analysis focuses on two biotech companies, Altimmune and Viking Therapeutics, which are developing GLP-1-targeted medicines for obesity, aiming to compete with established products from Eli Lilly and Novo Nordisk [8] Company Analysis Viking Therapeutics - Viking's lead candidate, VK2735, has shown promising results in its phase 2b clinical trial, with participants losing an average of 15.6% of their mass over 48 weeks [7][9] - The company is well-capitalized with $963 million in cash and equivalents, and it has no debt, which positions it favorably for commercialization [20] - Viking's pipeline includes non-GLP-1 programs, providing additional avenues for growth and reducing reliance on a single product [13] Altimmune - Altimmune's lead program is nearing the end of phase 2 trials, with strong interim data suggesting a likely continuation to phase 3 trials [11] - The company has $182 million in cash and equivalents, with total expenses of $89 million, indicating it can sustain operations but may need to raise additional funds for commercialization [22] - Altimmune's candidate may preserve muscle mass during weight loss, which could appeal to specific demographics such as seniors and those with mobility issues [21][18] Market Position - Both companies are positioned to capture market share in the obesity treatment sector, with Viking slightly ahead in terms of market readiness [9][19] - The absence of direct competition for Altimmune in its segments may provide a strategic advantage [12] - The potential for both companies to succeed in their clinical trials and secure regulatory approval in the coming years is high, making them attractive investment opportunities [19]

LLY $918.00 52-Week Range $434.34 $928.60 P/E Ratio 135.20 By all accounts, Eli Lilly's Tirzepatide, the active ingredient in Mounjaro and Zepbound, is superior on paper to Semaglutide, the active ingredient in Ozempic and Wegovy, because it targets two hormones compared to one. However, currently in Phase 2 clinical trials, its secret weapon for weight loss targets three hormones as the ultimate triple threat. Eli Lilly operates in the medical sector, facing competition from upcoming GLP-1 contenders from ...

LLY Eli Lilly and Company Today Eli Lilly and Company $904.76 -0.62 (-0.07%) 52-Week Range $434.34 $915.79 Dividend Yield 0.57% P/E Ratio 133.25 Price Target $812.72 Add to Watchlist Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used off-label for weight loss. Zepbound is prescribed for obesity treatment. The active ingredient in both is Tirzepatide. Lilly submi ...

Relyvrio Being Pulled From The Market For ALS Was A Setback, But A New Possibility Emerges AMX0035 Has Two Shots On Goal To Possibly Boost Shareholder Value Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) suffered a major setback this year when it voluntarily delisted its Amyotrophic lateral sclerosis [ALS] drug Relyvrio on April 4th of 2024. This was a huge blow to the company, definitely, but that doesn't mean that it doesn't have some opportunities to redeem itself in the coming years. What I'm talking about ...

Additional research demonstrates 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission "Standards of care for cardiometabolic health are evolving thanks to new GLP-1 medications, but research, including Dario's newest study, continues to demonstrate the importance of effective behavior change. These medications require the meaningful and sustainable change that Dario delivers for our members and our clients to support full realization of the value of these drugs," said Omar ...

~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ "This partnership brings together Rani's oral biologics delivery expertise with ProGen's two decades of experience in Fc-fusion proteins to enable development of a potentially unique ora ...

According to May's employment situation report (NFP), the U.S. economy added 272,000 jobs during the month. The healthcare industry took down 68,300 employees, or roughly 25.1%. More than that, Janus Henderson, Eli Lilly's largest shareholder, decided to boost its already sizeable stake in the stock in the past quarter. A 7.3% boost as of May 2024 brought the asset manager's position up to $2.8 billion today. There's always a good reason for markets to push stocks near their 52-week highs. Investors can now ...

Editor's note: Seeking Alpha is proud to welcome Evan Urbanski as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Trevor Williams Pixabay via Pexels KEY HIGHLICHTS → Current guidance suggests revenues between $292 million for Q2 24 (40%-43% YoY growth) and FY 2024 revenues at between $1.2 billion and $1.3 billion (38%-41% Y ...

"You have to be a really good student of the business and understand it inside and out and understand the industry," she told CNBC in an interview before her departure announcement. "Only when we understand the full system, can we navigate it well so that we bring value to it…That's my role as CFO." Eli Lilly's boom in revenue has allowed the company to invest heavily to scale up manufacturing, which will eventually get more medicine into patients' hands, Ashkenazi said. Ashkenazi, who will step in as the n ...